article thumbnail

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

PharmaShots

Shots: The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. The preliminary results from the monotx.

article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab. percent of the total mRNA therapy market by 2029. percent of the total mRNA therapy market by 2029.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

GlobalData stated that if development is successful for Ultragenyx’s OTX-2002 , which has potential to be the first programmable epigenetic medicine, it could generate $1.6 billion during 2028. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

article thumbnail

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

Initially developed to treat viral infections, mRNA vaccines deliver a piece of genetic material that instructs the body to make a protein fragment of a target pathogen (such as a virus), which the immune system recognises and remembers 1 to respond to when exposed to the pathogen in the future.

Vaccines 105
article thumbnail

Acetaminophen interactions to avoid

The Checkup by Singlecare

Acetaminophen may also blunt the effects of other medications that impact the immune system, including some medicines used to manage cancer diagnoses and even the immune response following vaccinations. In 2002, the FDA Nonprescription Advisory Committee (NDAC) reviewed safety data related to its use.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.

article thumbnail

A history of blood cancer treatment

pharmaphorum

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 2002 – Emergence of CAR-T therapy. Virchow was the first to argue that cancer derives from changes in normal cells. 1907 – The magic bullet of immunotherapy.